CELR / BTC

ACH / TRY

ACH / USDT

ACH / BTC

ZRO / USDT

ZRO / USDC

ZRO / TRY

WIF / EUR

ZRO / BTC

ZRO / FDUSD

CTXC / USDT

CTXC / BTC

SNT / ETH

SNT / USDT

SLP / ETH

AMP / TRY

AMP / USDT

ARPA / BTC

ID / BTC

BEAMX / TRY

WOL 3D INDIA LIMITED

VIBHOR STEEL TUBES LTD

MANUGRAPH INDIA LIMITED

SANGINITA CHEMICALS LTD

RAJESH EXPORTS LTD

EURO PANEL PRODUCTS LTD

SML ISUZU LIMITED

SPECIALITY REST LTD

LIKHITHA INFRASTRUC LTD

STEEL EXCHANGE INDIA LTD

KEI INDUSTRIES LTD.

ROCKINGDEALS CIRCU ECO L

NEELAM LINENS & GAR (I) L

P S RAJ STEELS LIMITED

PRAXIS HOME RETAIL LTD

PRAMARA PROMOTIONS LTD

ADROIT INFOTECH LIMITED

KHANDWALA SECURITIES LTD

PREMIUM PLAST LIMITED

SHREE TIRUPATI BALAJEE L

Click here to get full coverage on Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) - PR Newswire

Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)  PR Newswire

Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) - PR Newswire

Click here to get full coverage on The FDA Finally Visited an Indian Drug Factory Linked to U.S. Deaths. It Found Problems. - ProPublica

The FDA Finally Visited an Indian Drug Factory Linked to U.S. Deaths. It Found Problems.  ProPublica

The FDA Finally Visited an Indian Drug Factory Linked to U.S. Deaths. It Found Problems. - ProPublica

Click here to get full coverage on Glenmark Pharmaceuticals secures US FDA approval for Olopatadine ophthalmic solution - CNBCTV18

Glenmark Pharmaceuticals secures US FDA approval for Olopatadine ophthalmic solution  CNBCTV18

Glenmark Pharmaceuticals secures US FDA approval for Olopatadine ophthalmic solution - CNBCTV18

Click here to get full coverage on Stocks to Watch Today: Manappuram Finance, Hero MotoCorp, Hindalco, Glenmark, TCS, Lloyds Metals, CDSL, RailTel in focus on 21 March - TradingView

Stocks to Watch Today: Manappuram Finance, Hero MotoCorp, Hindalco, Glenmark, TCS, Lloyds Metals, CDSL, RailTel in focus on 21 March  TradingView

Stocks to Watch Today: Manappuram Finance, Hero MotoCorp, Hindalco, Glenmark, TCS, Lloyds Metals, CDSL, RailTel in focus on 21 March - TradingView

Click here to get full coverage on #GlenmarkPharmaceuticals secures #USFDA approval for Olopatadine ophthalmic solution - linkedin

#GlenmarkPharmaceuticals secures #USFDA approval for Olopatadine ophthalmic solution  linkedin

#GlenmarkPharmaceuticals secures #USFDA approval for Olopatadine ophthalmic solution - linkedin

Click here to get full coverage on Glenmark Pharma- Receives FDA Approval For Olopatadine Hydrochloride Ophthalmic Solution - Marketscreener.com

Glenmark Pharma- Receives FDA Approval For Olopatadine Hydrochloride Ophthalmic Solution  Marketscreener.com

Glenmark Pharma- Receives FDA Approval For Olopatadine Hydrochloride Ophthalmic Solution - Marketscreener.com

Click here to get full coverage on Glenmark issues another recall, this time for nearly 1.5M bottles of generic ADHD drug - FiercePharma

Glenmark issues another recall, this time for nearly 1.5M bottles of generic ADHD drug  FiercePharma

Glenmark issues another recall, this time for nearly 1.5M bottles of generic ADHD drug - FiercePharma

Click here to get full coverage on Glenmark recalls 1.5 million bottles of ADHD medication in US: USFDA - Business Standard

Glenmark recalls 1.5 million bottles of ADHD medication in US: USFDA  Business Standard

Glenmark recalls 1.5 million bottles of ADHD medication in US: USFDA - Business Standard

Click here to get full coverage on Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials - BioSpace

Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials  BioSpace

Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials - BioSpace

Click here to get full coverage on Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreate - GlobeNewswire

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreate  GlobeNewswire

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreate - GlobeNewswire

Click here to get full coverage on Nearly 1.5 Million Bottles of Glenmark's ADHD Drug Atomoxetine Recalled - MedCentral

Nearly 1.5 Million Bottles of Glenmark's ADHD Drug Atomoxetine Recalled  MedCentral

Nearly 1.5 Million Bottles of Glenmark's ADHD Drug Atomoxetine Recalled - MedCentral

Click here to get full coverage on The FDA Hasn’t Inspected This Drug Factory After 7 Recalls for the Same Flaw, 1 Potentially Deadly - ProPublica

The FDA Hasn’t Inspected This Drug Factory After 7 Recalls for the Same Flaw, 1 Potentially Deadly  ProPublica

The FDA Hasn’t Inspected This Drug Factory After 7 Recalls for the Same Flaw, 1 Potentially Deadly - ProPublica

Click here to get full coverage on Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC) - PR Newswire

Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC)  PR Newswire

Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC) - PR Newswire

Click here to get full coverage on Trio of Indian drugmakers issue recalls tied to impurity, labeling issues - FiercePharma

Trio of Indian drugmakers issue recalls tied to impurity, labeling issues  FiercePharma

Trio of Indian drugmakers issue recalls tied to impurity, labeling issues - FiercePharma

Click here to get full coverage on Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting - GlobeNewswire

Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting  GlobeNewswire

Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting - GlobeNewswire

Click here to get full coverage on Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial - PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial  PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial - PR Newswire

Click here to get full coverage on Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1% - PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1%  PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1% - PR Newswire

Click here to get full coverage on Glenmark joins growing list of drugmakers to settle long-running US price-fixing claims - FiercePharma

Glenmark joins growing list of drugmakers to settle long-running US price-fixing claims  FiercePharma

Glenmark joins growing list of drugmakers to settle long-running US price-fixing claims - FiercePharma

Click here to get full coverage on Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules - PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules  PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules - PR Newswire

Click here to get full coverage on Glenmark acquires Acetylcysteine injection, launches in US market - The Economic Times

Glenmark acquires Acetylcysteine injection, launches in US market  The Economic Times

Glenmark acquires Acetylcysteine injection, launches in US market - The Economic Times

Click here to get full coverage on Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) - PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL)  PR Newswire

Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) - PR Newswire

Click here to get full coverage on Trispecific antibody from Ichnos Glenmark Innovation beats J&J's Tecvayli at treating multiple myeloma in mice - Fierce Biotech

Trispecific antibody from Ichnos Glenmark Innovation beats J&J's Tecvayli at treating multiple myeloma in mice  Fierce Biotech

Trispecific antibody from Ichnos Glenmark Innovation beats J&J's Tecvayli at treating multiple myeloma in mice - Fierce Biotech

Click here to get full coverage on Merck, Glenmark Lose Bid to Toss Claims in Zetia Antitrust Case - Bloomberg Law

Merck, Glenmark Lose Bid to Toss Claims in Zetia Antitrust Case  Bloomberg Law

Merck, Glenmark Lose Bid to Toss Claims in Zetia Antitrust Case - Bloomberg Law

Click here to get full coverage on 15 Lakh Bottles Of ADHD Medication Recalled In U.S. By Glenmark - NDTV

15 Lakh Bottles Of ADHD Medication Recalled In U.S. By Glenmark  NDTV

15 Lakh Bottles Of ADHD Medication Recalled In U.S. By Glenmark - NDTV

Click here to get full coverage on Glenmark, FDC recall products in US due to manufacturing issues: USFDA - The Economic Times

Glenmark, FDC recall products in US due to manufacturing issues: USFDA  The Economic Times

Glenmark, FDC recall products in US due to manufacturing issues: USFDA - The Economic Times

Click here to get full coverage on Glenmark shares in focus after recall of 15 lakh bottles of ADHD drug in US - The Economic Times

Glenmark shares in focus after recall of 15 lakh bottles of ADHD drug in US  The Economic Times

Glenmark shares in focus after recall of 15 lakh bottles of ADHD drug in US - The Economic Times

Click here to get full coverage on Aurobindo Pharma, Glenmark recall products in US - The Economic Times

Aurobindo Pharma, Glenmark recall products in US  The Economic Times

Aurobindo Pharma, Glenmark recall products in US - The Economic Times

Click here to get full coverage on Glenmark recalls ADHD medicine bottles in US - The Times of India

Glenmark recalls ADHD medicine bottles in US  The Times of India

Glenmark recalls ADHD medicine bottles in US - The Times of India

Click here to get full coverage on Glenmark Eyes Generic Flovent Launch In Coming Months Amid Expected US Resurgence - Citeline News & Insights

Glenmark Eyes Generic Flovent Launch In Coming Months Amid Expected US Resurgence  Citeline News & Insights

Glenmark Eyes Generic Flovent Launch In Coming Months Amid Expected US Resurgence - Citeline News & Insights

Click here to get full coverage on Glenmark To Pay $7 Million To Settle Lawsuits With Three Entities In US - NDTV Profit

Glenmark To Pay $7 Million To Settle Lawsuits With Three Entities In US  NDTV Profit

Glenmark To Pay $7 Million To Settle Lawsuits With Three Entities In US - NDTV Profit

Click here to get full coverage on Glenmark arm recalls two products in US due to manufacturing issues - Business Standard

Glenmark arm recalls two products in US due to manufacturing issues  Business Standard

Glenmark arm recalls two products in US due to manufacturing issues - Business Standard

Click here to get full coverage on Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC) - PR Newswire

Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC)  PR Newswire

Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC) - PR Newswire

Click here to get full coverage on Glenmark launches Empagliflozin for diabetes in India under Glempa brand - Business Standard

Glenmark launches Empagliflozin for diabetes in India under Glempa brand  Business Standard

Glenmark launches Empagliflozin for diabetes in India under Glempa brand - Business Standard

Click here to get full coverage on Glenmark Launches Latanoprost Ophthalmic Solution - Contract Pharma

Glenmark Launches Latanoprost Ophthalmic Solution  Contract Pharma

Glenmark Launches Latanoprost Ophthalmic Solution - Contract Pharma

Click here to get full coverage on Glenmark Hit With $50M Suit Over Potassium Pill Death - Law360

Glenmark Hit With $50M Suit Over Potassium Pill Death  Law360

Glenmark Hit With $50M Suit Over Potassium Pill Death - Law360

Click here to get full coverage on Glenmark Pharma arm acquires and launches Acetylcysteine injection in US - CNBCTV18

Glenmark Pharma arm acquires and launches Acetylcysteine injection in US  CNBCTV18

Glenmark Pharma arm acquires and launches Acetylcysteine injection in US - CNBCTV18

Click here to get full coverage on Glenmark recalls 114 batches of low potassium drug in the US over potentially deadly hyperkalemia risk - FiercePharma

Glenmark recalls 114 batches of low potassium drug in the US over potentially deadly hyperkalemia risk  FiercePharma

Glenmark recalls 114 batches of low potassium drug in the US over potentially deadly hyperkalemia risk - FiercePharma

Click here to get full coverage on Glenmark Pharma Q3 Results: Company Reports Profit, Revenue Rises 35% - NDTV Profit

Glenmark Pharma Q3 Results: Company Reports Profit, Revenue Rises 35%  NDTV Profit

Glenmark Pharma Q3 Results: Company Reports Profit, Revenue Rises 35% - NDTV Profit

Click here to get full coverage on Glenmark Pharma's US arm launches drug to treat blood clotting issues - Business Standard

Glenmark Pharma's US arm launches drug to treat blood clotting issues  Business Standard

Glenmark Pharma's US arm launches drug to treat blood clotting issues - Business Standard

Click here to get full coverage on Glenmark Pharmaceuticals Q3 Results: PAT at Rs 348 crore versus YoY loss, revenue up 35% - The Economic Times

Glenmark Pharmaceuticals Q3 Results: PAT at Rs 348 crore versus YoY loss, revenue up 35%  The Economic Times

Glenmark Pharmaceuticals Q3 Results: PAT at Rs 348 crore versus YoY loss, revenue up 35% - The Economic Times

Click here to get full coverage on Glenmark Pharma shares in focus after 34% stake acquisition in O2 renewable energy XXIV - The Economic Times

Glenmark Pharma shares in focus after 34% stake acquisition in O2 renewable energy XXIV  The Economic Times

Glenmark Pharma shares in focus after 34% stake acquisition in O2 renewable energy XXIV - The Economic Times

Click here to get full coverage on Corporate Chaos: Glenmark Faces Backlash Over Abrupt Job Cuts - Medical Dialogues

Corporate Chaos: Glenmark Faces Backlash Over Abrupt Job Cuts  Medical Dialogues

Corporate Chaos: Glenmark Faces Backlash Over Abrupt Job Cuts - Medical Dialogues

Click here to get full coverage on Glenmark launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC) - Business Standard

Glenmark launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC)  Business Standard

Glenmark launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC) - Business Standard

Click here to get full coverage on Glenmark Pharma gains on settling U.S. antitrust lawsuits for $7 million - Business Standard

Glenmark Pharma gains on settling U.S. antitrust lawsuits for $7 million  Business Standard

Glenmark Pharma gains on settling U.S. antitrust lawsuits for $7 million - Business Standard

Click here to get full coverage on Glenmark Pharma enters settlement pact with Humana, Centene, Kaiser for $7 million, denies all allegations - CNBCTV18

Glenmark Pharma enters settlement pact with Humana, Centene, Kaiser for $7 million, denies all allegations  CNBCTV18

Glenmark Pharma enters settlement pact with Humana, Centene, Kaiser for $7 million, denies all allegations - CNBCTV18

Click here to get full coverage on Glenmark Pharma launches osmotic laxative Polyethylene Glycol in US - Business Standard

Glenmark Pharma launches osmotic laxative Polyethylene Glycol in US  Business Standard

Glenmark Pharma launches osmotic laxative Polyethylene Glycol in US - Business Standard

Click here to get full coverage on Glenmark agrees to market BeiGene’s oncology medicines in India - Pharmaceutical Technology

Glenmark agrees to market BeiGene’s oncology medicines in India  Pharmaceutical Technology

Glenmark agrees to market BeiGene’s oncology medicines in India - Pharmaceutical Technology

Click here to get full coverage on Glenmark Pharmaceuticals Q2 results 2024 on 16 Nov, 2024: profit at ₹354.21Cr, Revenue increased by 7.06% YoY - Mint

Glenmark Pharmaceuticals Q2 results 2024 on 16 Nov, 2024: profit at ₹354.21Cr, Revenue increased by 7.06% YoY  Mint

Glenmark Pharmaceuticals Q2 results 2024 on 16 Nov, 2024: profit at ₹354.21Cr, Revenue increased by 7.06% YoY - Mint

Click here to get full coverage on Glenmark rises on Lacosamide Oral, equivalent of anti-epileptic drug with $57 million in annual sales - Moneycontrol

Glenmark rises on Lacosamide Oral, equivalent of anti-epileptic drug with $57 million in annual sales  Moneycontrol

Glenmark rises on Lacosamide Oral, equivalent of anti-epileptic drug with $57 million in annual sales - Moneycontrol

Click here to get full coverage on Glenmark Pharma stages smart recovery in Q3 with ₹348-crore net profit on higher revenues - CNBCTV18

Glenmark Pharma stages smart recovery in Q3 with ₹348-crore net profit on higher revenues  CNBCTV18

Glenmark Pharma stages smart recovery in Q3 with ₹348-crore net profit on higher revenues - CNBCTV18

Click here to get full coverage on Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India - PR Newswire

Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India  PR Newswire

Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India - PR Newswire

Click here to get full coverage on Glenmark Pharma launches Travoprost ophthalmic solution in US - CNBCTV18

Glenmark Pharma launches Travoprost ophthalmic solution in US  CNBCTV18

Glenmark Pharma launches Travoprost ophthalmic solution in US - CNBCTV18

Click here to get full coverage on Glenmark Life Sciences renamed as Alivus Life Sciences - Business Standard

Glenmark Life Sciences renamed as Alivus Life Sciences  Business Standard

Glenmark Life Sciences renamed as Alivus Life Sciences - Business Standard

Click here to get full coverage on Glenmark announces acquisition and launch of Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials - Business Standard

Glenmark announces acquisition and launch of Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials  Business Standard

Glenmark Pharmaceuticals Limited (GLENMARK)

Price Chart

Key Statistics

Technicals

About GLENMARK

Latest News

Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) - PR Newswire

The FDA Finally Visited an Indian Drug Factory Linked to U.S. Deaths. It Found Problems. - ProPublica

Glenmark Pharmaceuticals secures US FDA approval for Olopatadine ophthalmic solution - CNBCTV18

Advanced Charts

Top Gainers

Top Losers